Home > Physicians > Medical Education > Med Ed Programs > Pediatric Acute Myeloid Leukemia: Advances, Evidence, and the Future

CME Program

Pediatric Acute Myeloid Leukemia: Advances, Evidence, and the Future

Order CD

http://www.marrow.org/medorder
(no CME credit available)

Program Description

This program will describe the latest evidence in the management of pediatric acute myeloid leukemia. Dr. Frank Smith will discuss risk group stratification, options for treatment and current outcomes. He will also describe upcoming studies that will address comparative treatments.

Faculty

Frank Smith, M.D.
Marjory J. Johnson Endowed Chair
Professor of Pediatrics,
University of Cincinnati College of Medicine
Director, Division of Hematology / Oncology,
Cincinnati Children's Hospital Medical Center

Learning Objectives

Identify patients at high risk for disease progression at diagnosis, and beyond
List current treatment options and outcomes based on prognostic factors
Determine the appropriate timing and use of transplantation and list factors affecting outcomes for this therapy
Discuss outstanding research questions and upcoming clinical trials

Goal

The goal of this program is to improve participant understanding of the treatment of pediatric patients with AML.

Target Audience

This activity is intended for hematologists, oncologists and other health care professionals who are involved in the treatment of patients with pediatric acute myeloid leukemia.

Accreditation and Certification

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint sponsorship of the Medical College of Wisconsin, the National Marrow Donor Program^® and the Center for International Blood & Marrow Transplant Research^TM. The Medical College of Wisconsin (MCW) is accredited by the ACCME to provide continuing medical education for physicians.

The Medical College of Wisconsin designates this educational activity for a maximum of 1.0 AMA PRA Category 1 credit(s)^TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Support

This activity is supported by an educational grant from Genzyme Corporation provided to the National Marrow Donor Program, through its funding partner, The Marrow Foundation^®.

Questions

If you have questions regarding this program, call Renee Ryan at (800)526-7809 ext. 8430.

E-mail a Friend

Print this Page